研究成果： |
滕乐生博士已作为项目负责人承担科研项目35项，其中国家及省部级项目14项，获得经费2300余万元；共发表SCI论文176余篇，被引频次7700余次，h因子为48，其中代表性论文发表在Nature Biomedical Engineering，Nature Communications，Acta Pharmaceutica Sinica B，Journal of Controlled Release，Biomaterials，Nano Letters等杂志上。获授权发明专利24项，其中以第一发明人身份授权8项。 代表性论文： 1. Zhaogang Yang#, Junfeng Shi#, Jing Xie, Yifan Wang, Jingyao Sun, Tongzheng Liu, Yarong Zhao, Xiuting Zhao, Xinmei Wang, Yifan Ma, Veysi Malkoc, Chiling Chiang, Weiye Deng, Yuanxin Chen, Yuan Fu, Kwang J. Kwak, Yamin Fan, Chen Kang, Changcheng Yin, June Rhee, Paul Bertani, Jose Otero, Wu Lu, Kyuson Yun, Andrew S. Lee, Wen Jiang, Lesheng Teng*, Betty Y. S. Kim* and L. James Lee*, Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation, Nature Biomedical Engineering, 2020, 4(1), 69-83. (影响因子：29.2) 2. Shiyan Dong, Xuan Liu, Ye Bi, Yifan Wang, Abin Antony, DaeYong Lee, Kristin Huntoon, Seongdong Jeong, Yifan Ma, Xuefeng Li, Weiye Deng, Benjamin R. Schrank, Adam J. Grippin, JongHoon Ha, Minjeong Kang, Mengyu Chang, Yarong Zhao, Rongze Sun, Xiangshi Sun, Jie Yang, Jiayi Chen, Sarah K. Tang, L. James Lee, Andrew S. Lee, Lirong Teng, Shengnian Wang*, Lesheng Teng*, Betty Y. S. Kim*, Zhaogang Yang* and Wen Jiang*. Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer. Nature Communications, 2023,14(1): 6610. (影响因子：16.6) 3. Shuangshuang Hu#, Wenzhe Yi#, Zhiwen Zhao, Xindi Qian, Linyang Jiang, Ying Cao, Dan Yan, LeshengTeng*, Yaping Li*. A lymph node-targeted cell-nanoadjuvant conjugate enhances dendritic cell-T cell crosstalk for cancer immunotherapy, Acta Pharmaceutica Sinica B, 2026,16(6):3876-3891. (影响因子：14.6) 4. Ye Bi, Sensen Xie, Ziwei Li, Shiyan Dong*, Lesheng Teng*. Precise nanoscale fabrication technologies, the “last mile” of medicinal development. Acta Pharmaceutica Sinica B, 2025, 15(5): 2372-2401. (影响因子：14.6) 5. Huan Zhang, Jie Yang, Rongze Sun, Songren Han, Zhaogang Yang, Lesheng Teng*, Microfluidics for nano-drug delivery systems: From fundamentals to industrialization. Acta Pharmaceutica Sinica B. 2023, 13(8):3277-3299. (影响因子：14.6) 6. Yunshuang Jiao, Jicong Chen, Huijia Lei, Siyuan Hu, Yuanhao Yu, Jinsheng Yang, Yuyang Chen, Jie Yang*, LeshengTeng*. Neutrophil-Mediated Drug Delivery Nanoplatform Constructed from Celastrol Loaded Liposome for Targeted Therapy of Rheumatoid Arthritis. Nano Letters, 2026, 25;26(7):2381-2388. (影响因子：9.5) 7. Huan Zhang, Jianming Xing, Man Sun, Yaxin Cui, Yulai Li, Siyuan Hu, Xinhe Wang, Hao Jiang, Yun Zhang, Xuanjie Jiang, Fang Yang, Betty Y S Kim, Wen Jiang, Zhaogang Yang*, Lesheng Teng*. Engineered exosomes for targeted microRNA delivery to reverse liver fibrosis. Biomaterials, 2026, 324:123510. (影响因子：12.9) 8. Zhao Yarong, Liu Luotong, Sun Rongze, Cui Guilin, Guo Shuyu, Han Songren, Li Ziwei, Bai, Tian*, Teng, Lesheng*. Exosomes in cancer immunoediting and immunotherapy. Asian Journal of Pharmaceutical Sciences. 2022, 17(2):193-205. (影响因子：12.6) 9. Zhao Yarong, Yu Yang, Wang Simiao, Li Jiaxin, Teng, Lesheng*. Small extracellular vesicles encapsulating lefty1 mRNA inhibit hepatic fibrosis. Asian Journal of Pharmaceutical Sciences. 2022, 17(5): 630-640. (影响因子：12.6) 10. Shiyan Dong,Ye Bi, Xiangshi Sun, Yarong Zhao, Rongze Sun, Fei Hao, Yating Sun, Yifan Wang, Xuefeng Li, Weiye Deng, Xuan Liu, JongHoon Ha, Lirong Teng, Ping Gong, Jing Xie, Betty Y.S. Kim, Zhaogang Yang*, Wen Jiang*. Lesheng Teng*, Dual-loaded liposomes tagged with hyaluronic acid have synergistic effects in triple-negative breast cancer. Small. 2022,18(16), 2107690. (影响因子：11.9) 代表性科研项目： 1. 国家自然科学基金面上项目，基于工程化外泌体靶向重塑胃癌免疫微环境与逆转免疫逃逸的协同治疗研究，项目批准号：82674009，2027.01-2030.12，49万元，主持 2. 国家自然科学基金面上项目，靶向调控肿瘤相关成纤维细胞改善肿瘤微环境联合PD-1抑制剂协同治疗结直肠癌的应用及机制研究，项目批准号：82473373，2025.01-2028.12，49万元，主持 3. 国家自然科学基金面上项目，具备肿瘤杀伤及逆转肿瘤微环境的载药功能化中性粒细胞的构建及其在非小细胞肺癌治疗中的应用，项目批准号：82073784，2021/01-2025/03，56万元，主持 4. 吉林省第二十批创新创业人才资助项目，具有调节小胶质细胞表型的工程化外泌体构建及其通过靶向小胶质细胞治疗AD的研究，2024.03-2026.12，25万，主持 5. 中科佰瑞(长春)生物科技有限公司，新型细胞制品的制备及功效评价，2024.12.3-2034.12.3，1000万元，主持 |
